Acute Leukaemia (AML, APL, ALL, Burkitt’s Leukaemia)
Avapritinib Monotherapy
Indication
00937a
As monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy
azaCITIDine (Oral) Monotherapy
Indication
00818a
Maintenance treatment in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation (HSCT).
azaCITIDine75mg/m2 5-2-2 Therapy
Indication
00287d
Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to WHO classification.
00287e
AML with > 30% marrow blasts according to the WHO classification
azaCITIDine100mg/m2 5 day Therapy
Indication
00288d
Acute myeloid leukaemia (AML) with 20-30% blasts and multilineage dysplasia, according to WHO classification.
00288e
AML with > 30% marrow blasts according to the WHO classification
Intermediate Dose Cytarabine Therapy
Indication
00364a
Consolidation therapy for the treatment of patients Acute Myeloid Leukaemia (AML)
High Dose Cytarabine Therapy
Indication
00365a
Consolidation therapy for the treatment of patients with Acute Myeloid Leukaemia (AML)
Intrathecal Cytarabine 50mg
Indication
00870a
Central Nervous System (CNS) prophylaxis and treatment in patients with Acute Myeloid Leukaemia (AML)
00870b
CNS treatment in patients with Acute Lymphoblastic Leukaemia (ALL)
Intrathecal Cytarabine 70mg
Indication
00871a
Central Nervous System (CNS) prophylaxis and treatment in patients with Acute Myeloid Leukaemia (AML)
00871b
CNS treatment in patients with Acute Lymphoblastic Leukaemia (ALL)
DA(60/100) (3+10) Course 1 Induction Therapy (AML-17)
Indication
00359a
Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)
DA(50/100) (3+8) Course 2 Induction Therapy (AML-17)
Indication
00360a
Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)
Decitabine Monotherapy – AML (28 day cycle)
Indication
00231a
Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the WHO classification, who are not candidates for standard induction chemotherapy.
FLAG Therapy
Indication
00363a
Treatment of Acute Myeloid Leukaemia (AML) in patients unsuitable for treatment with IDArubicin or as consolidation post FLAG-Ida
00363c
Salvage regimen for patients with relapsed/refractory acute leukaemia
FLAG:Ida 8mg/m2 Therapy
Indication
00362a
Induction chemotherapy regimen for the treatment of patients with de novo, secondary Acute Myeloid Leukaemia (AML), or biphenotypic leukaemia.
00362c
Salvage regimen for patients with relapsed/refractory acute leukaemia
Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML indication)
Indication
00612a
Gemtuzumab ozogamicin is indicated for combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukaemia
Gilteritinib Therapy
Indication
00684a
As monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.
Hydroxycarbamide Therapy
Hyper CVAD (ALL) Therapy - Part A
Indication
00824a
Treatment of adult patients ≥ 25 years with Philadelphia chromosome (Ph) negative acute lymphoblastic leukaemia
riTUXimab Hyper CVAD (ALL) Therapy - Part A
Indication
00825a
Treatment of adult patients ≥ 25 years with CD20 positive, Philadelphia chromosome (Ph) negative acute lymphoblastic leukaemia
Hyper CVAD (ALL) Therapy - Part B (Patients ≤ 60 years)
Indication
00826a
Treatment of adult patients 25-60 years with Philadelphia chromosome (Ph) negative acute lymphoblastic leukaemia
Hyper CVAD (ALL) Therapy - Part B (Patients > 60 years)
Indication
00932a
Treatment of adult patients > 60 years with Philadephia chromosome (Ph) negative acute lymphoblastic leukaemia
riTUXimab Hyper CVAD (ALL) Therapy - Part B (Patients ≤ 60 years)
Indication
00827a
Treatment of adult patients 25-60 years with CD20 positive, Philadelphia chromosome (Ph) negative acute lymphoblastic leukaemia
riTUXimab Hyper CVAD (ALL) Therapy - Part B (Patients > 60 years)
Indication
00933a
Treatment of adult patients > 60 years with CD20 positive, Philadelphia chromosome (Ph) negative acute lymphoblastic leukaemia
Hyper CVAD (ALL) Maintenance Therapy (POMP)
Indication
00912a
Maintenance therapy for adult patients ≥ 25 years with Philadelphia chromosome (Ph) negative acute lymphoblastic leukaemia
Intrathecal Methotrexate for haematological malignancies
Indication
00869a
Central Nervous System (CNS) prophylaxis and treatment in patients with Acute Myeloid Leukaemia (AML)
00869b
CNS treatment in patients with Acute Lymphoblastic Leukaemia (ALL)
Midostaurin Maintenance Therapy
Indication
00661a
Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.
Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy
Indication
00682a
Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive
Midostaurin (Intermediate Dose Cytarabine) Consolidation Therapy
Indication
00683a
Midostaurin is indicated in combination with intermediate dose cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.
Vyxeos liposomal® (DAUNOrubicin and Cytarabine) Induction Therapy
Indication
00613a
For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Vyxeos liposomal® (DAUNOrubicin and Cytarabine) Consolidation Therapy
Indication
00618a
For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Triple Intrathecal Therapy
Indication
00873a
Triple Intrathecal Therapy for treatment of Central Nervous System (CNS) disease in patients with Acute Lymphoblastic Leukaemia.
00873b
Treatment of Central Nervous System (CNS) disease in patients with Acute Myeloid Leukaemia (AML)
Tretinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy
Indication
00356a
Treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL) (defined as WCC count ≤ 10x109 /L)
00356b
Treatment of adult patients with relapsed or refractory APL after ATRA/chemotherapy
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy
Indication
00357a
Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356).
Tretinoin (ATRA) IDArubicin (PETHEMA AIDA) Induction Therapy:High Risk
Indication
00366a
Treatment of patients with newly diagnosed high risk Acute Promyelocytic Leukaemia (APL)
Triple Intrathecal Therapy
Indication
00873a
Triple Intrathecal Therapy for treatment of Central Nervous System (CNS) disease in patients with Acute Lymphoblastic Leukaemia.
00873b
Treatment of Central Nervous System (CNS) disease in patients with Acute Myeloid Leukaemia (AML)
Blinatumomab Therapy
Indication
00538a
Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).
Blinatumomab Therapy (ALL with MRD ≥ 0.1%)
Indication
00590a
As monotherapy for the treatment of adults with Philadelphia
chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%
Inotuzumab ozogamicin Monotherapy
Indication
00537a
Monotherapy for the treatment of adults with relapsed or refractory CD22- positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).
PONATinib Therapy
Indication
00302b
Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy
Indication
00886a
Quizartinib in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.
Quizartinib and Intermediate Dose Cytarabine Consolidation Therapy
Indication
00887a
Quizartinib in combination with cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.
Quizartinib, IDArubicin and Cytarabine Induction Therapy
Indication
00891a
Quizartinib in combination with standard IDArubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive
Quizartinib Maintenance Therapy
Indication
00888a
As monotherapy for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.
UKALL14 Phase 1 Standard Induction Therapy
Indication
00874a
Induction of remission in newly diagnosed, previously untreated adult acute lymphoblastic leukaemia (ALL) patients (aged 25–65 years) treated on UKALL14-protocol.
UKALL14 Phase 2 Standard Induction Therapy
Indication
00875a
Induction of remission in newly diagnosed previously untreated Adult Acute Lymphoblastic Leukaemia (ALL) patients (aged 25–65 years) treated on UKALL14-protocol following Phase 1 Induction Therapy
UKALL 14 Intensification/CNS Prophylaxis Therapy
Indication
00876a
Treatment of adult patients (aged 25–65 years) with newly diagnosed, previously untreated acute lymphoblastic leukaemia (ALL) following Phase 2 Induction Therapy
UKALL14v12 Consolidation Phase Cycle 1
Indication
00877a
Treatment of adult patients (aged 25–65 years) with newly diagnosed, previously untreated acute lymphoblastic leukaemia (ALL) treated on UKALL14-protocol who are in remission but not eligible for allogeneic transplantation following treatment with Intensification/CNS Prophylaxis regimen
UKALL14v12 Consolidation Phase Cycle 2 and 4
Indication
00878a
Treatment of adult patients(aged 25–65 years) with newly diagnosed, previously untreated acute lymphoblastic leukaemia (ALL) treated on UKALL14-protocol who are in remission but not eligible for allogeneic transplantation following treatment with Consolidation Phase 1 (for Cycle 2) and Consolidation Phase 3 (for Cycle 4)
UKALL14v12 Consolidation Phase Cycle 3
Indication
00879a
Treatment of adult patients (aged 25–65 years) with newly diagnosed, previously untreated Acute Lymphoblastic Leukaemia (ALL) treated on UKALL14- protocol who are in remission but not eligible for allogeneic transplantation following treatment with Consolidation Phase 2
UKALL14v12 Maintenance Therapy
Indication
00881a
Treatment of adult patients (aged 25–65 years) with newly diagnosed, previously untreated Acute Lymphoblastic Leukaemia (ALL) treated on UKALL14- protocol who are in remission but not eligible for allogeneic transplantation following treatment with Consolidation Phase Cycle 4
Venetoclax and azaCITIDine Therapy
Indication
00852a
Venetoclax in combination with azaCITIDine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy
Myeloid Neoplasms (CML, MDS, PV, PMF)
Asciminib Therapy
Indication
00847a
Treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase (CP), who have previously been treated with two or more tyrosine kinase inhibitors (TKIs).
azaCITIDine75mg/m2 5-2-2 Therapy
Indication
00287c
Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
azaCITIDine100mg/m2 5-day Therapy
Indication
00288c
Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
Bosutinib Monotherapy
Indication
00224a
Treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+CML previously treated with one or more TKI(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
azaCITIDine75mg/m2 5-2-2 Therapy
Indication
00287a
Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).
00287b
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Intermediate-2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).
azaCITIDine100mg/m2 5-day Therapy
Indication
00288a
Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).
00288b
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Intermediate-2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).
FLAG Therapy
Indication
00363b
Treatment of patients with high blast count (>10%) Myelodysplastic Syndrome in patients unsuitable for treatment with IDArubicin.
FLAG: Ida 8mg/m2 Therapy
Fedratinib Therapy
Indication
00788a
For the treatment of disease-related splenomegaly or symptoms in adult patients with: primary myelofibrosis (PMF),post polycythaemia vera myelofibrosis (PVMF) or post essential thrombocythaemia myelofibrosis (ET MF) who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib
Hydroxycarbamide Therapy
Indication
00581a
Treatment for patients with high risk myeloproliferative neoplasms
00581b
Treatment of leucocytosis in AML and CML
Momelotinib Therapy
Indication
00867a
For the treatment of disease-related splenomegaly or symptoms in adult patients with: Moderate to severe anaemia who have primary myelofibrosis, Post polycythaemia vera myelofibrosis or
Post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
PONATinib Therapy
Indication
00302a
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Peginterferon alfa-2a Therapy
Indication
00883a
As monotherapy in adults for the treatment of polycythaemia vera.
00883b
As monotherapy in adults for the treatment of essential thrombocythaemia.
00883c
As monotherapy for the treatment of primary or secondary myelofibrosis (post-essential thrombocythemia or post -polycythemia vera.
Ruxolitinib Monotherapy
Indication
00229a
Primary myelofibrosis (chronic idiopathic myelofibrosis)
00229b
Post polycythaemia vera myelofibrosis
00229c
Post essential thrombocythaemia myelofibrosis